文献速递泌尿生殖与妇科肿瘤放疗

NRG肿瘤学RTOG 0938中患者报告结局:评估两种前列腺癌超低分次放疗方案

Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2018-06-18

NRG肿瘤学RTOG 0938是一项非盲随机2期研究,纳入国家综合癌症网络低危前列腺癌患者,随机接受5次(7.25 Gy/2周)或12次(4.3 Gy/2.5周)超低分次放疗。基于EPIC-50肠道和泌尿域变化及急晚期毒性,两种方案耐受良好,但需与当前标准放疗方案比较。

要点

  • 5次组1年EPIC-50肠道评分变化>5分的频率为29.8%(P<.001),12次组为28.4%(P<.001)。
  • 5次组1年EPIC-50泌尿评分变化>2分的频率为45.7%(P<.001),12次组为42.2%(P<.001)。
  • 无晚期4级或5级治疗相关泌尿或肠道毒性。

核心结论

  • 基于肠道和泌尿域变化及急晚期毒性,5次和12次方案耐受良好。
  • 这些超低分次方法需与当前标准放疗方案进行比较。

研究设计与样本

  • NRG肿瘤学RTOG 0938是一项非盲随机2期研究,纳入国家综合癌症网络低危前列腺癌患者,每个臂与历史对照比较。
  • 患者随机接受5次(7.25 Gy/2周)或12次(4.3 Gy/2.5周)放疗。
  • 共同主要终点为1年时EPIC-50肠道评分变化>5分和泌尿评分变化>2分的患者比例,采用单样本二项检验。
  • 研究入组5次组127例(分析121例)和12次组128例(分析125例)。
  • 分析时所有患者中位随访时间为3.8年。

主要发现

  • 1年肠道评分变化>5分的频率在5次组为29.8%(P<.001),在12次组为28.4%(P<.001)。
  • 1年泌尿评分变化>2分的频率在5次组为45.7%(P<.001),在12次组为42.2%(P<.001)。
  • 5次组中32.9%的患者1年EPIC-50性功能评分下降≥11分(P=.34);12次组中30.9%的患者1年EPIC-50性功能评分下降≥11分(P=.20)。
  • 2年无病生存率在5次组为99.2%(95%置信区间:97.5-100),在12次组为97.5%(95%置信区间:94.6-100)。
  • 无晚期4级或5级治疗相关泌尿或肠道毒性。

关键数值与推荐

  • 1年肠道评分变化>5分的频率:5次组29.8%(P<.001),12次组28.4%(P<.001)。
  • 1年泌尿评分变化>2分的频率:5次组45.7%(P<.001),12次组42.2%(P<.001)。
  • 1年EPIC-50性功能评分下降≥11分的频率:5次组32.9%(P=.34),12次组30.9%(P=.20)。
  • 2年无病生存率:5次组99.2%(95%置信区间:97.5-100),12次组97.5%(95%置信区间:94.6-100)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 这些超低分次方法需与当前标准放疗方案进行比较。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There is considerable interest in very short (ultrahypofractionated) radiation therapy regimens to treat prostate cancer based on potential radiobiological advantages, patient convenience, and resource allocation benefits. Our objective is to demonstrate that detectable changes in health-related quality of life measured by the bowel and urinary domains of the Expanded Prostate Cancer Index Composite (EPIC-50) were not substantially worse than baseline scores. METHODS AND MATERIALS: NRG Oncology's RTOG 0938 is a nonblinded randomized phase 2 study of National Comprehensive Cancer Network low-risk prostate cancer in which each arm is compared with a historical control. Patients were randomized to 5 fractions (7.25 Gy in 2 weeks) or 12 fractions (4.3 Gy in 2.5 weeks). The co-primary endpoints were the proportion of patients with a change in EPIC-50 bowel score at 1 year (baseline to 1 year) >5 points and in EPIC-50 urinary score >2 points tested with a 1-sample binomial test. RESULTS: The study enrolled 127 patients to 5 fractions (121 analyzed) and 128 patients to 12 fractions (125 analyzed). Median follow-up for all patients at the time of analysis was 3.8 years. The 1-year frequency for >5 point change in bowel score were 29.8% (P < .001) and 28.4% (P < .001) for 5 and 12 fractions, respectively. The 1-year frequencies for >2 point change in urinary score were 45.7% (P < .001) and 42.2% (P < .001) for 5 and 12 fractions, respectively. For 5 fractions, 32.9% of patients had a drop in 1-year EPIC-50 sexual score of ≥11 points (P = .34); for 12 fractions, 30.9% of patients had a drop in 1-year EPIC-50 sexual score of ≥ 11 points (P = .20). Disease-free survival at 2 years is 99.2% (95% confidence interval: 97.5-100) in the 5-fraction arm and 97.5% (95% confidence interval: 94.6-100) in the 12-fraction arm. There was no late grade 4 or 5 treatment-related urinary or bowel toxicity. CONCLUSIONS: This study confirms that, based on changes in bowel and urinary domains and toxicity (acute and late), the 5- and 12-fraction regimens are well tolerated. These ultrahypofractionated approaches need to be compared with current standard radiation therapy regimens.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Lukka HR, Pugh SL, Bruner DW, et al. Patient Reported Outcomes in NRG Oncology RTOG 0938, Evaluating Two Ultrahypofractionated Regimens for Prostate Cancer. Int J Radiat Oncol Biol Phys. 2018. PMID: 29913254. doi:10.1016/j.ijrobp.2018.06.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。